Blood Disorder Treatments
The global market for blood disorder treatments increased from $34.8 billion in 2006 to an estimated $36.7 billion by the end of 2007. It should reach nearly $44.0 billion by 2012, a compound annual growth rate (cagr) of 3.9%.
Anemia, hemophilia, neutropenia and thrombosis treatments are all slated for growth due to advances in diagnostics and drug design.
The thrombosis treatment segment accounts for the largest portion of revenues and is expected to be worth $16.4 billion by 2012.
This BCC report details the Market for Blood Disorder Treatments. The market is rapidly growing due to recent advancements in pharmaceutical products, advancements in drug delivery of medications and accurate diagnosis. Emphasis has been placed on early detection and treatment of disorders. There are issues surrounding this market that are currently in the news that will ultimately shape this market for the future. An assessment of this market is presented to ensure that participants in the market do not get caught off guard, not having time to prepare for the future developments.
The objectives of the study are to heighten the awareness of blood disorders, their consequences and their treatments. The study analyzes pharmaceutical entities that are currently on the market and new products that are on the horizon.
SCOPE OF STUDY
This report contains:
- Descriptions of various types of blood disorder treatments for anemia, hemophilia, neutropenia and thrombosis
- The current market status of blood disorder treatments, trends and forecasts for growth over the next 5 years
- Discussion of new technologies with a thorough patent analysis
- Analysis of the major overhaul of the U.S. Food and Drug Administration's approval process for blood disorder treatments
- Profiles of major players in the blood disorder treatment market.
METHODOLOGY AND INFORMATION SOURCES
The information and analysis presented in this BCC Research report are based on extensive first-hand interviews with primary executives, product managers, and clinical specialists in the area of blood disorders. Background information was obtained from various government, business, medical, and hematology journals and trade magazines, as well as interviews with hematologists, physicians, and nurses involved in hematological conditions. Key information from published literature was used to conduct interviews with industry participants to validate and obtain expert opinions on current and future trends in the area of blood disorders. Interviews were also conducted to confirm and/or adjust market size and market share estimates, as well as to formulate market projections.
All market data pertain to revenues at the manufacturer's level. Data are expressed in current U.S. dollars. The base year was 2007. Historical data are provided for 2005 and 2006, and forecast data are provided for 2012. Historical, base year, and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2007 base year.
For 2003, the total worldwide market for blood disorder treatments was estimated at $25.4 billion. Rising at an average annual growth rate (AAGR) of 6.7%, the market is expected to exceed $35 billion by 2008.
The prescription anemia pharmaceutical treatment segment accounts for the largest portion of revenues, with $10 billion in 2003 but is growing at a slower pace than the overall market, at 5.9%.
Prescription thrombosis treatments, the second largest segment, will account for about $12.3 billion in 2008, up from $9.2 billion in 2003.
Rising the fastest are treatments for neutropenia at an AAGR of 9%, and will reach nearly $4.6 billion in 2008.